Loading
Angiodynamics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Oct 2025.
Angiodynamics Inc: what insiders have been doing
Angiodynamics Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 14 insiders published 43 filings.
On the market, 1 insider bought (1 purchase totalling €102k) while 1 insider sold (1 sale totalling €300k). Netting one side against the other leaves €198k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive. One trade stands out by size: a sale of €300k from Nighan Warren JR, disclosed on 31 July 2026, or 0.053% of market capitalisation.
Compared with its exchange (5,458 companies, median 22 filings), a count of 43 filings is above the norm. The full history, which starts in 2021, counts 11 purchases against 7 sales. The 10-K for the year ended 31 May 2026 shows 320.2 m USD of revenue and -36.7 m USD of net income.
In the case of 1 purchase, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 361 days ago, on 22 October 2025. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
224
Thresholds
n/a
Buy Volume
€783,079
11 ops. · all time
Sell Volume
€804,077
7 ops. · all time
Who traded when
BuySaleWarren Nighan Jr.2 sales
James C. Clemmer1 buy
Lawrence T. Weiss1 buy
Stephen A. Trowbridge1 buy
Since the insiders bought
- -11.9%Entry US$12.00 · Close at T+90 US$10.57
- -14.9%Entry US$11.83 · Close at T+90 US$10.07
- -8.6%Entry US$11.00 · Close at T+90 US$10.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Angiodynamics Inc Strong Buy (bullish), based on 4 analysts. Average price target: US$19.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,164 of 24,148 companies
28.0
score / 100
Value29
Quality28
FCF yld0.1%
Earn yld-7.8%
EV/EBITDA·
ROE-19%
Gross mgn55%
Net mgn-11%
Debt/EBITDA7.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended May 2024 · cache
US$11.24
Analyst consensus
4 analystsStrong buy
US$17.00Target US$19.75(+76%)US$24.00
Income statement
RevenueUS$320.2M
Gross profitUS$174.9M55% margin
EBITDAUS$626k0% margin
Net income-US$36.7M-10.1% margin
Valuation
PER (forward)-99.2x
P/Book2.9x
Beta0.30
Balance sheet & cash
Market capUS$472.7M
Total debtUS$4.7M
Free Cash FlowUS$508k
Debt / Equity7%
Profitability & ownership
ROE-19.2%
ROA-5.1%
% insiders13.1%
% institutions92.7%
Last declaration on 31 July 2026
Declarations224 total
23,370 shares@ US$14.720.053% mcap69.0% of flowCommon StockSEC:0001140361-26-030514:0
23,370 shares@ US$14.71990.053% mcap100.0% of flowCommonSEC144:0001950047-26-007444
52,358 shares0Common StockSEC:0001140361-26-029633:0
16,296 shares0Common StockSEC:0001140361-26-029634:0
5,694 shares0Common StockSEC:0001140361-26-029635:0
8,047 shares0Common StockSEC:0001140361-26-029636:0
6,466 shares0Common StockSEC:0001140361-26-029632:0
2,330 shares@ US$13.820.0050% mcap9.9% of flowCommon StockSEC:0001140361-26-029632:1
26,728 shares@ US$13.820.058% mcap16.6% of flowCommon StockSEC:0001140361-26-029633:1
8,319 shares@ US$13.820.018% mcap15.3% of flowCommon StockSEC:0001140361-26-029634:1
1,671 shares@ US$13.820.0036% mcap4.7% of flowCommon StockSEC:0001140361-26-029635:1
4,506 shares@ US$13.820.0097% mcap23.3% of flowCommon StockSEC:0001140361-26-029636:1
21,288 shares0Common StockSEC:0001140361-26-029330:0
16,081 shares0Common StockSEC:0001140361-26-029331:0
17,966 shares0Common StockSEC:0001140361-26-029332:0
19,860 shares0Common StockSEC:0001140361-26-029333:0
53,257 shares0Common StockSEC:0001140361-26-029334:0
11,887 shares0Common StockSEC:0001140361-26-029335:0
11,887 shares0Common StockSEC:0001140361-26-029336:0
11,887 shares0Common StockSEC:0001140361-26-029337:0
11,887 shares0Common StockSEC:0001140361-26-029338:0
11,887 shares0Common StockSEC:0001140361-26-029339:0
11,887 shares0Common StockSEC:0001140361-26-029340:0
11,887 shares0Common StockSEC:0001140361-26-029341:0
11,764 shares@ US$13.510.025% mcap7.1% of flowCommon StockSEC:0001140361-26-029178:2
25 of 224 declarations
About Angiodynamics Inc
AngioDynamics Inc. (ticker: ANGO) is a U.S.-based medical technology company listed on the NASDAQ in the United States. Founded in 1988 in Queensbury, New York, and later relocating its corporate headquarters to Latham, New York in 2010, the company has developed into a focused specialist in minimally invasive devices used for peripheral vascular disease and selected cancer therapies. Its NASDAQ listing and its positioning in interventional healthcare make it a closely watched name for investors seeking exposure to medtech innovation, clinical adoption, and product-cycle execution.
AngioDynamics’ business is organized around a mix of growth-oriented “Med Tech” platforms and a broader “Med Device” portfolio. The Med Tech franchise includes NanoKnife, the company’s irreversible electroporation system used in ablation therapy; Auryon, its peripheral atherectomy platform for peripheral artery disease; and AngioVac and AlphaVac, which are used in mechanical thrombectomy and aspiration-based clot removal. The broader device portfolio also includes vascular access products such as implantable ports and PICCs, angiographic accessories, drainage products, thrombolytic products, and venous solutions. This portfolio breadth gives the company multiple commercial touchpoints, but it also places AngioDynamics in a highly competitive market against larger global medtech peers with greater scale and distribution reach.
Read moreShow less
Geographically, AngioDynamics sells in the United States through a direct sales force, while international sales are handled through a combination of direct channels and distributors. That footprint reflects a company that remains predominantly U.S.-anchored operationally, with headquarters in Latham, New York, but with a broader global commercialization strategy. The company’s competitive edge is built less on commoditized devices and more on differentiated technology, clinical evidence, and incremental regulatory clearances that can expand the use cases for its platforms.
Recent developments have reinforced the company’s transformation narrative. In April 2026, AngioDynamics reported fiscal third-quarter 2026 results showing continued double-digit growth in its Med Tech segment and reiterated that the segment has been a key driver of overall performance. The company also raised full-year fiscal 2026 guidance for the third consecutive quarter, while maintaining a debt-free balance sheet and reporting $37.8 million in cash at the end of February 2026. In May 2026, AngioDynamics announced two-year PRESERVE trial data for NanoKnife in intermediate-risk prostate cancer, which is an important clinical update for a core growth asset. For investors, ANGO remains a U.S. NASDAQ-listed medtech company with meaningful upside tied to product adoption, clinical validation, and execution, but it also carries the usual sector risks related to regulation, reimbursement, competition, and manufacturing transitions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
